Skip to main content

Table 2 Vaccine-specific model parameters

From: Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia

Parameter PHiD-CV PCV13 Rangea PSA distribution
Vaccination ages (months) 2, 4 and 13 2, 4 and 13 Not varied NA
Vaccination coverage (%) 100 [28] 100 [28] Not varied NA
Vaccine cost (USD/dose) 34.25 (hypothetical price) 34.25 (hypothetical price) Not varied NA
VEs/effectivenesses (%)
 IPD
  Vaccine serotypes (excluding ST3) 94.7 (based on PCV7 data [31]) 94.7 (based on PCV7 data [31]) 95% CIb Lognormal
  ST3 0 (assumption) 26 (based on PCV13 data [32]) Not varied NA
  Cross-protection for ST6A 76.0 (based on PCV7 data [31, 36]) NA 95% CIc Lognormal
  Cross-protection for ST19A 82.2 (based on PHiD-CV surveillance [14]) NA 95% CIc Lognormal
 All-cause pneumonia
  Hospitalized 21.8 (based on PHiD-CV data [17]) 21.8 (based on PHiD-CV data [17]) 95% CI Lognormal
  GP visit 8.7 (based on PHiD-CV data [17]) 8.7 (based on PHiD-CV data [17]) 95% CI Lognormal
 All-cause AOM
  Vaccine serotypes (excluding ST3) 69.9 (based on PHiD-CV data [17]) 69.9 (based on PHiD-CV data [17]) 95% CI Lognormal
  Cross-protection for ST6A 63.7 (based on PHiD-CV precursor data [18]) NA Not variedc NA
  Cross-protection for ST19A 61 (based on PHiD-CV and PCV7 data [14, 17, 31])d NA Not variedc NA
  ST3 0 (assumption) 0 (assumption due to a lack of relevant data) Not varied NA
  Non-vaccine serotypes –33 (based on PCV7 data [43]) –33 (based on PCV7 data [43]) 95% CI Lognormal
  NTHi 21.5 (based on PHiD-CV data [17]) –11 (based on PCV7 data [43]) 95% CI Lognormal
  Overall 24.1 (based on the above and pathogen split from [41, 42]) 14.2 (based on the above and pathogen split from [41, 42]) Not varied NA
  1. AOM acute otitis media, CI, confidence interval, GP general practitioner, IPD invasive pneumococcal disease, NA not applicable, NTHi non-typeable Haemophilus influenzae, PCV7 7-valent pneumococcal conjugate vaccine, PCV13 13-valent pneumococcal conjugate vaccine, PHiD-CV pneumococcal polysaccharide and NTHi protein D conjugate vaccine, ST serotype, USD United States dollars, VE vaccine efficacy, PSA probabilistic sensitivity analysis
  2. aRanges used in the one-way sensitivity analyses
  3. bLowest and highest vaccine-type 95% CIs from [31] used for all serotypes
  4. cNot applicable for PCV13
  5. dEstimated based on PHiD-CV VE against 19A IPD [14], PCV7 VE against vaccine serotype IPD [31], and PHiD-CV VE against vaccine serotype AOM [17]